A cherry-flavored pill, sized and dosed for the smallest possible patients, has just cleared one of the biggest regulatory hurdles in global health. The World Health Organization has pre-qualified the first malaria treatment specifically designed for newborns and infants weighing between 2 and 5 kilograms, a milestone that could save millions of young lives in the years ahead. With 30 million babies born every year in malaria-endemic regions of Africa, the urgency is hard to overstate. Before this drug existed, doctors treating infected newborns had no purpose-built medicine to reach for. They improvised doses of adult formulations, a gamble that left babies either over-medicated and suffering severe side effects, or under-dosed and vulnerable to the disease returning.
Why newborns were left without a safe option
Malaria is most lethal for children under five, and the cruelest window is the first months of life. Infants cannot receive the malaria vaccine until around 5 months old, which means a newborn who contracts the disease in that gap has almost no protection. The new drug uses the same active medicine as older treatments, but it pairs a smaller dose with additional ingredients specifically formulated to block the side effects that made improvised dosing so dangerous. The company behind it is based in Switzerland, and after receiving Swiss regulatory approval in July of last year, the drug was adopted by Ghana in October, making it the first African country to use it. Eight African nations have since approved it, and the WHO pre-qualification now means international procurement organizations including UNICEF and the Global Fund can begin purchasing and distributing it at scale.
The malaria news does not stop there. The WHO simultaneously approved three new diagnostic tests capable of identifying infections significantly faster than existing tools. And the broader fight against malaria is already showing results. Early data from the first-generation malaria vaccines, rolled out across 25 African countries since 2024, shows more than 50 million doses administered, with Kenya, Malawi, Cameroon, and Ghana all reporting steep drops in severe infections and hospital admissions. Vaccines in those countries are over 70% effective at preventing cases during the first year. The results from Burkina Faso were described as even more striking: malaria deaths among children under five fell by 50% in a single year. The goal now is to fully vaccinate an additional 50 million children by 2030.
A pharmacist, a centrifuge, and a simpler way to save lives
Elsewhere in medicine, German scientists have developed what may be the cheapest method yet to produce universal blood plasma. The challenge has always been blood type compatibility. In emergencies, when a patient’s blood type is unknown, doctors typically reach for type AB blood, the only type compatible with everyone, but also one of the rarest, making it expensive and difficult to stockpile. A team at a German university hospital found a way to strip the problematic antibodies out of ordinary A, B, and O blood plasma by introducing a small amount of red blood cells from another type, allowing the antibodies to bind to them, then spinning the mixture in a centrifuge to remove the combined complex. ‘It is quite simple,’ said the pharmacist leading the project, and that simplicity is the entire point. The method works with equipment already found in any blood bank, meaning it requires no specialist infrastructure to implement. Germany’s top health authority has already approved the technique, and the team hopes to begin supplying it to patients before the end of the year.
The centrifuge sitting in every blood bank
A standard centrifuge, the same machine already running in hospital labs worldwide, is what makes the universal plasma process possible. No specialized hardware, no new facility, just a reconfigured protocol applied to existing equipment.
The cherry-flavored pill for newborns did not appear from nowhere. It followed decades of researchers, pharmacists, and public health workers identifying a gap that the medical system had long treated as too small to fill, and deciding that was not good enough. Now the gap has a solution, small enough to dissolve on a baby’s tongue, and precise enough to finally get the dose right.
